JP2007516966A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516966A5
JP2007516966A5 JP2006542741A JP2006542741A JP2007516966A5 JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5 JP 2006542741 A JP2006542741 A JP 2006542741A JP 2006542741 A JP2006542741 A JP 2006542741A JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5
Authority
JP
Japan
Prior art keywords
seq
cells
cancer
synthetic peptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006542741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516966A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/040347 external-priority patent/WO2005053618A2/en
Publication of JP2007516966A publication Critical patent/JP2007516966A/ja
Publication of JP2007516966A5 publication Critical patent/JP2007516966A5/ja
Pending legal-status Critical Current

Links

JP2006542741A 2003-12-01 2004-11-30 合成hla結合ペプチド類似体及びその使用方法 Pending JP2007516966A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52595503P 2003-12-01 2003-12-01
PCT/US2004/040347 WO2005053618A2 (en) 2003-12-01 2004-11-30 Synthetic hla binding peptide analogues and uses thereof

Publications (2)

Publication Number Publication Date
JP2007516966A JP2007516966A (ja) 2007-06-28
JP2007516966A5 true JP2007516966A5 (cg-RX-API-DMAC7.html) 2008-01-17

Family

ID=34652399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542741A Pending JP2007516966A (ja) 2003-12-01 2004-11-30 合成hla結合ペプチド類似体及びその使用方法

Country Status (7)

Country Link
US (3) US7488718B2 (cg-RX-API-DMAC7.html)
EP (2) EP2478913A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007516966A (cg-RX-API-DMAC7.html)
AU (1) AU2004294345B2 (cg-RX-API-DMAC7.html)
CA (1) CA2548135C (cg-RX-API-DMAC7.html)
ES (1) ES2402184T5 (cg-RX-API-DMAC7.html)
WO (1) WO2005053618A2 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127409A1 (en) * 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) * 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
JP2010504332A (ja) * 2006-09-19 2010-02-12 ヒューマン バイオモレキュラル リサーチ インスティテュート アルツハイマー病の診断方法及び遺伝子マーカー
MX352947B (es) * 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
US20100255020A1 (en) * 2007-11-20 2010-10-07 Nec Corporation Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
WO2009072610A1 (ja) * 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
CA2760041A1 (en) * 2008-05-14 2009-11-19 Simons Haplomics Limited Methods and compositions for the treatment of cancer
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2013018778A1 (ja) 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP3520810A3 (en) * 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20240408197A1 (en) * 2015-11-20 2024-12-12 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
HUE059694T2 (hu) 2015-11-20 2022-12-28 Memorial Sloan Kettering Cancer Center Készítmény rák kezelésére
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
US12059463B2 (en) 2017-10-24 2024-08-13 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法
CN114149970B (zh) * 2021-11-09 2024-06-18 因诺伟(北京)生物医疗科技有限公司 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
NZ521430A (en) * 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos

Similar Documents

Publication Publication Date Title
JP4480580B2 (ja) Wt1置換型ペプチド
EP2385117B1 (en) HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
DK2547364T3 (en) Peptides, conjugates and methods for increasing the immunogenicity of a vaccine
JP6367950B2 (ja) 前立腺癌治療用組成物
JP6266811B2 (ja) 血管新生病の免疫療法
WO2016146261A1 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
TWI455721B (zh) 癌疫苗組合物
WO2005095598A1 (ja) Wt1由来の癌抗原ペプチド
EP3094652A1 (en) Novel vaccines against hpv and hpv-related diseases
JP2007516966A (ja) 合成hla結合ペプチド類似体及びその使用方法
ES2805829T3 (es) Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno
BRPI0708737A2 (pt) mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural
NO309798B1 (no) Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
BR112019018616A2 (pt) peptídeos e métodos para o tratamento de diabetes
RU2012136530A (ru) Новые соединения, влияющие на пищевое поведение
TW201000119A (en) MYBL2 epitope peptides and vaccines containing the same
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
JP2022513209A (ja) オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物
AU2015365606B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
CN101072875B (zh) 新型癌抗原肽及其用途
US20160213746A1 (en) Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
TWI496579B (zh) 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途
JP2001514659A (ja) ドラスタチン−15誘導体とタキサンとの併用
JP2002538166A (ja) Mhcクラスiiによって提示されるmage−3由来免疫原性ペプチドおよびその使用
WO2012015979A2 (en) Hmgb1-derived peptides enhance immune response to antigens